The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Biosimilar Contract Manufacturing Market Change Between 2026 And 2030?
The biosimilar contract manufacturing market has seen rapid expansion in recent years. Its valuation is anticipated to climb from $9.94 billion in 2025 to $11.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.7%. This historical growth can be primarily attributed to the expiry of reference biologic patents, the early embrace of biosimilar development programs, the broadening of contract manufacturing partnerships, evolving regulatory directives for biosimilars, and an increase in the occurrence of chronic diseases.
The biosimilar contract manufacturing market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $20.35 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.4%. The expansion throughout the projected timeframe can be ascribed to several factors, including a rise in biosimilar authorizations across international markets, increasing impetus to lower biologic treatment expenses, the broadening of biosimilar product pipelines, escalating investments in substantial manufacturing capabilities, and progress in process optimization technologies. Key trends expected during this forecast period encompass a surge in the outsourcing of biosimilar production, an escalating need for economical production platforms, a heightened emphasis on analytical and quality assurance services, the broadening of mammalian cell-based manufacturing, and a stronger focus on adherence to regulatory standards.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp
What Are The Main Drivers Accelerating The Growth Of The Biosimilar Contract Manufacturing Market?
The increasing incidence of diabetes is anticipated to fuel the expansion of the biosimilar contract manufacturing market in the future. Diabetes prevalence signifies the percentage of individuals within a population suffering from diabetes at a specific moment, indicating a continuous requirement for treatment and a lifelong demand for therapy. This increase in diabetes prevalence stems from more inactive lifestyles and unhealthy eating patterns, resulting in obesity, insulin resistance, and elevated instances of type 2 diabetes. Biosimilar contract manufacturing aids diabetes management by facilitating the extensive, economical production of biosimilar insulin and associated biologics. It guarantees consistent quality and adherence to regulations, thereby making advanced treatments more obtainable for patients. This contributes to greater affordability of treatment and broadens worldwide availability of crucial diabetes care. For example, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the expanding prevalence of diabetes is propelling the growth of the biosimilar contract manufacturing market.
How Does Segment Analysis Break Down The Biosimilar Contract Manufacturing Market Structure?
The biosimilar contract manufacturing market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Other Product Types
2) By Service Type: Process Development, Analytical And Quality Control, Fill And Finish Operations, Packaging, Other Service Types
3) By Source: Mammalian, Non-mammalian
4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
5) By End-Use: Pharmaceutical Companies, Biotech Companies
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Insulin: Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin
3) By Erythropoietin: Alpha Erythropoietin, Beta Erythropoietin, Darbepoetin Alfa, Continuous Erythropoietin Receptor Activators
4) By Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, Long Acting Granulocyte Colony-Stimulating Factor
5) By Other Product Types: Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, Hormonal Biologics
What Trends Are Driving Changes In The Biosimilar Contract Manufacturing Market?
Major companies within the biosimilar contract manufacturing market are concentrating on developing production facilities, particularly mirrored single-use plants, to accelerate technology transfer, enhance scale-up capabilities, and improve commercial reliability. Mirrored single-use plants are sites constructed with identical production suites that operate using disposable bioprocess equipment and unified digital systems, thereby enabling rapid operational changes, consistent quality across various locations, and a reduced risk of contamination. For instance, in September 2025, Rezon Bio, a Poland-based contract development and manufacturing organization (CDMO), launched two single-use biomanufacturing sites with mirrored capabilities, covering services from cell line development through to commercial GMP supply. This approach facilitates faster technology transfer and flexible scale-up for biosimilars with minimized downtime, while simultaneously improving batch-to-batch consistency through standardized suites, integrated analytics, and logistics automation. It also lowers the total cost of ownership for sponsors by reducing cleaning validation requirements, shortening both development and manufacturing timelines, and decreasing the risks associated with expansion.
Which Industry Players Are Present In The Biosimilar Contract Manufacturing Market?
Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.
Access The Complete Biosimilar Contract Manufacturing Market Report:
Which Region Leads The Biosimilar Contract Manufacturing Market By Size?
North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biosimilar Contract Manufacturing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=30215&type=smp
Browse Through More Reports Similar to the Global Biosimilar Contract Manufacturing Market 2026, By The Business Research Company
Biopharmaceuticals Contract Manufacturing Market Report 2026
Medical Device Contract Manufacturing Market Report 2026
Food Contract Manufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/food-contract-manufacturing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model